Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Zai Lab and Amgen reach a global clinical research collaboration
Zai Lab Co., Ltd. today announced that it has reached a global clinical research collaboration with Amgen, aiming to evaluate the antibody-drug conjugate (ADC) zocilurtatug pelitecan (zoci, formerly ZL-1310) targeting delta-like ligand 3 (DLL3) in the clinical stage in combination with Amgen’s IMDELLTRA (tarlatamab-dlle), a DLL3-targeted bispecific T-cell engager (BiTE) therapy, for the treatment of patients with extensive-stage small cell lung cancer (ES-SCLC). As part of this collaboration agreement, Amgen will apply to initiate a global Phase 1b study to evaluate the safety and efficacy of zoci combined with IMDELLTRA in ES-SCLC patients. Zai Lab will retain full ownership of zoci and will provide Amgen with clinical trial study drugs.